LncRNA HEIH expression in cancer prognosis: A review and meta- analysis

Abstract

Background: Several studies have shown that HEIH is overexpressed in a variety of cancers and plays a role as an oncogene in cancer. The present meta-analysis aims to elucidate the relationship between HEIH expression and prognosis and clinicopathological features among cancer patients.Materials and methods: PubMed, Web of Science, Cochrane Library, and EMBASE database were comprehensively and systematically searched. pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence interval (CI) were employed to assess the relationship between HEIH expression and clinical outcomes and clinicopathological features in cancer patients.Results: The present study finally enrolled 11 studies which included 1227 cancer patients. The combined results indicated that HEIH overexpression was significantly associated with shorter overall survival (OS) (pooled HR=2.03, 95% CI 1.74–2.38, P < 0.00001).Meanwhile, regarding clinicopathology of cancer patients, upregulated HEIH expression was closely related to larger tumor size (OR = 2.65, 95% CI: 1.52–4.65, P = 0.0006), advanced tumor T stage (OR = 2.41, 95 % CI: 1.54–3.77, P = 0.0001), advanced TNM stage (OR = 4.76, 95% CI: 2.73–8.29, P < 0.00001), distant metastasis (OR = 2.94, 95% CI: 1.75–4.96, P < 0.0001) and lymph node metastasis (OR = 2.07, 95% CI: 1.05–4.07, P = 0.04), respectively.Conclusions: High expression of HEIH in some cancers predicts shorter overall survival and higher clinical stage as well as larger tumor size. HEIH has great potential to become a prognostic marker for cancer patients.